Clinical Trial

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-10-08; most recent amendment 2026-02-18.
Status change: Recruiting → Active, Not Recruiting 2024-05-01
Status change: Not Yet Recruiting → Recruiting 2023-01-06
Trial Details
NCT Number NCT05577000
Lead Sponsor Thomas Martin, MD
Collaborators: Actavis Inc., University of California, Davis, Eugia Pharma Specialities Limited
Conditions Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Enrollment 5 participants
Start Date 2021-10-18
Primary Completion 2025-11-30 (estimated)
Study Completion 2038-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-20